Niagen Bioscience 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Niagen Bioscience reported 3rd quarter 2026 net sales of $27.2 million; TruNiagen contributed $23.3 million, down 10% or $2.7 million year over year.
- TruNiagen direct-to-consumer website sales grew 13% year over year, or approximately 17% after adjusting for the timing of Prime Day-related promotions.
- Niagen ingredient revenue was $3.8 million, including $3.4 million of food-grade Niagen and $425,000 in pharmaceutical-grade Niagen.
- Gross margin was 62.9% in the 2nd quarter compared with 64.5% a year ago, a 160 basis point difference attributed to changes in product and business mix.
- Selling and marketing expense was $8.7 million, or 32% of net sales, compared with $8.8 million, or 25.8% of net sales, in the prior year quarter; research and development expense was $1.8 million.
- General and administrative expense was $8.2 million, an increase of approximately $1.1 million from the prior year quarter, primarily due to higher legal expenses.
- Net loss was negative $1.2 million, or $0.01 per diluted share, compared with net income of $0.06 per diluted share in the 3rd quarter of 2025.
- Adjusted EBITDA was reported as $450,000 in the CEO's remarks and $500,000 in the CFO's remarks; operating cash flow was approximately $2.6 million.
- The company ended the quarter with $69.5 million in cash, no debt, $83.3 million in working capital, and $14.6 million of authorization remaining under its $20 million share repurchase program.
- Management cited increasing competition from low-cost products, including NMN, and said pricing remains a hurdle for Niagen ingredient customers and end users.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience Inc.'s third quarter 2026 earnings conference call. My name is Connor, and I will be the Moderator today. At this time, all participants are in listen-only mode. As a reminder, this conference call is being recorded, and after today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. Earlier today, Niagen Bioscience issued a press release announcing its financial results for the third quarter of 2026. If you have not reviewed this information, it is available within the investor relations section of Niagen Bioscience's website at www.niagenbioscience.com. I would now like to turn the call over to Kendall Knysch, Senior Director, Publicity and Public Relations.
Good afternoon, and welcome to Niagen Bioscience Inc.'s third quarter 2026 conference call. Joining me today are our Chief Executive Officer, Rob Fried, Chief Financial Officer, Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will join for the Q&A. Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our relationships with major customers, general economic conditions, the market and size of the vitamin, mineral, and dietary supplement market, and the intravenous market, our research and development activities, expansion into new markets, business development opportunities, and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially.
For a discussion of these risks, please refer to our most recent Form 10-Q and other filings with the SEC. We undertake no obligation to update these statements except as required by law. In addition, we may reference certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures can be found in today's earnings release and presentation, both available in the investor relations section of our website. With that, it is now my pleasure to turn the call over to our Chief Executive Officer, Rob Fried.
Thank you, Kendall, and good afternoon, everyone, and thank you for joining us on today's investor call. We had a productive third quarter and are laying the foundation for growth with progress across all four pillars of Niagen's NAD platform: Tru Niagen Ingredients, Niagen Plus, and NAD Pharmaceuticals. Each business is well-positioned for significant growth in 2027, with 2026, as we have said before, focused mainly on investing and preparing for that expansion. While the market is experiencing changing dynamics, our core business remains resilient. Low-cost and low-quality products claiming to elevate NAD continue to enter the market. However, our website revenues grew approximately 10% year-over-year, or 17% year-over-year adjusted for Prime Day, which took place in the third quarter in 2025, continuing to demonstrate that there is increasing demand for the most researched, most effective, and highest-quality NAD-boosting supplement in the world, Tru Niagen.
In the third quarter, we generated approximately $2.6 million in positive operating cash flow and $450,000 of adjusted EBITDA. We ended the quarter with $69.5 million in cash, no debt, and $83.3 million in working capital, a $600,000 increase. Our mission is to improve the way people age through the world's leading NAD-boosting technologies. We are the global leader in NAD science, and we are applying our scientific expertise across consumer health, ingredients, clinics, skincare applications, and pharmaceuticals to participate in the larger healthy aging and longevity markets. As NAD continues to gain mainstream attention, we do see increased competition in the marketplace. The ingredients business, specifically one large customer, is experiencing continued competition from NMN and other products marketed as NAD supplements. Niagen NR is differentiated by the scope and depth of its supporting research.
However, pricing remains a hurdle to overcome for our ingredient customers and the end-user customer. Earlier this year, we have filed a lawsuit against the FDA regarding its decision on NMN. Our case is under review, and we will provide updates on material developments. Additionally, it's worth reminding to everyone listening that all of the commercially available NMN products are, we believe, infringing on existing patents, and those companies are willingly ignoring the rule of law. In late 2025, we acquired patents covering NR salt forms beyond NR chloride, and we are preparing one of those salt forms for commercialization. We believe it can be manufactured at significantly lower cost, with the potential to materially reduce cost of goods and our price to our ingredient customers, in return strengthening our ingredients business. We are completing ingredient qualification and expect to begin commercialization in early 2027.
Separately, just last week, the federal court handed down a favorable ruling that reversed the attorney's fee award against Niagen Bio and our patent litigation against Elysium. The court also rejected Elysium's request to remand the matter for further proceedings. This ruling is an important step forward towards closing this longstanding matter. As you know, Tru Niagen is the number one NAD-boosting oral supplement in the United States and one of the largest-selling single-ingredient supplement SKUs, period. We recently expanded our distribution to walmart.com, to nearly 300 GNC locations, and Sam's Club locations across 44 states. As we continue to invest in generating greater brand awareness, we plan to introduce additional healthy aging supplements within our Tru Niagen brand in 2027. Our goal is to build on the trust in our brand and the science behind it with products that support healthspan.
Speaking of new product offerings, we announced in October that Niagen NanoCloud is now a permanent offering available in our product portfolio, available on our website, on Amazon, and offered through select healthcare practitioners. This cements skincare as a category in our product portfolio. Through our partnership with one of the largest global skincare companies, we expect a topical product incorporating Niagen to reach the market in early 2027. And through our continued product innovation, we plan to launch a new branded skincare product in the first half of 2027. One of the investments we have made recently was in expanding awareness of the Niagen brand. We launched the Don't Get Old. Age Better. campaign, featuring 11-time world champion surfer Kelly Slater and more than 20 partners across sports, entertainment, and medicine.
Our objective is to make our science relevant to people who want to stay active as they age and give them a clear reason to choose Niagen. As with all major investments we make, we will evaluate the spend against customer acquisition and other learnings to optimize and maintain profitable growth. Niagen Plus is gaining traction in clinics. We have discussed previously that expanding our compounding pharmacy network would drive costs to end users down and make Niagen more competitive with NAD for IV and injection use. One of our larger clinic partners, Restore Hyper Wellness, has made Niagen a flagship offering and dedicated their longevity month promotion to Niagen IV and injections as their main offering in more than 200 locations.
The pricing that Restore provides to its customers was only made possible to the competitive dynamics we have introduced to the market, and we plan to continue to expand similar partnership structures with our other key clinic partners to grow patient awareness and education that Niagen is the better NAD. On October 22nd, we launched our first ready-to-inject liquid Niagen at-home injection kit. The simpler format avoids reconstitution and provides a superior product experience to our customers. Two recently published studies reported encouraging benefits during 90 days of at-home use. Our focus is to translate better access and a simpler product into continued consumer and patient adoption. As we continue to innovate our product offering on our telehealth platform, other large telehealth partners have expressed interest in offering our at-home injection kits on their own respective channels.
This is only the beginning for Niagen Plus, and we are very optimistic about our positioning for 2027. Our drug development program also advanced during the quarter. IND-enabling studies with Evotec have started, and our preclinical efficacy models are showing early signs of promise. Notably, NB4168 has demonstrated neuroprotective and lifespan-promoting effects in preclinical models. We plan to begin first in-human studies in 2027, subject to completion of the necessary development work and regulatory clearance. Prior clinical and preclinical research provides the foundation of our drug development efforts for additional rare diseases. Through our external research program, Tru Niagen was studied in Werner syndrome, Cockayne syndrome, Friedreich's ataxia, Citrin deficiency, in addition to ataxia-telangiectasia. Following the first in-human studies, we are evaluating conducting a basket-style phase II trial involving NB4168 and these additional orphan diseases, which could broaden the addressable patient population quite significantly.
We are also very encouraged by efforts to make rare disease development more practical. The FDA's new Rare Disease Framework Initiative aims to tailor evidence expectations to small patient populations and improve regulatory predictability. Separately, the federal bipartisan Faster Clinical Trials Act would establish trial networks in routine healthcare settings and improve connections between health records and research systems and further strengthen FDA support for flexible trial designs. If enacted, it could make trials easier to enroll and to conduct. Alongside FDA's work on natural history data and external controls, we believe these developments could help Niagen pursue additional rare disease indications more efficiently and reduce the economic burden of recruitment. The opportunity for NB4168 would depend on the available evidence and agreement with the FDA on an appropriate study design. Of course, scientific leadership remains the foundation of every business we operate.
Our work is supported by more than 300 research collaborations involving over 200 institutions in 34 countries, more than 225 peer-reviewed publications, including more than 50 published human clinical studies on Niagen, and a patent estate that exceeds 100 patents. The World Health Organization projects the global population age 60 and older will grow from 1.1 billion in 2023 to 1.4 billion by 2030. This not only represents a large market opportunity, but also represents a large opportunity for Niagen Bioscience to positively impact the way people age. We recently announced an agreement with Mass General Brigham for a large-scale prevention trial to evaluate the effect of Niagen supplementation on short and long-term major clinical and healthy aging outcomes and biomarkers. This partnership with MGB and with Dr. Howard Sesso is an important component of our long-term scientific program.
Dr. Sesso's work, including his role in the well-known COSMOS trial, even years later, continues to contribute valuable evidence in the field, and we believe this study can further advance NAD science and strengthen Niagen's position in healthy aging. I am quite proud of our leadership in the NAD industry and in our relationships with such esteemed researchers and institutions to further our understanding of how NAD-related interventions can affect health as people age. We are setting the foundation for strong growth in 2027 through continued growth of our product portfolio and offerings in Tru Niagen, evolved operations in the ingredients business, innovation and expanded clinic partner networks, and developments towards pharmaceutical opportunities.
With a strong balance sheet, no debt, a recognized brand, extensive scientific research, our objective is to convert scientific leadership rigor into a differentiated NAD platform to bring Niagen, the better NAD, to consumers, clinics, and pharmaceutical partners across the growing healthy aging and longevity markets. We will pursue that opportunity with discipline and a clear focus on customer and shareholder value. With that, I would now like to hand the call over to Ozan to run through the quarter's financials, and then on to Q&A and closing remarks.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
